NRIX

Nurix Therapeutics, Inc.

A clinical-stage biopharmaceutical company that designs small-molecule drugs to treat cancer and autoimmune diseases by hijacking the body's own protein-disposal system to remove disease-causing proteins. Founded in 2009 by scientists from UC Berkeley and UCSF, it was originally called Kura Therapeutics before taking the name Nurix in 2012. Its lead drug candidate, bexobrutideg, works by tagging and destroying a protein that fuels certain blood cancers.